 Today I have the distinct pleasure of speaking with Mike Druhan of medics health. How are you today Mike? Wonderful Tracy? How about you Mike? I'm a big fan of Animal Kingdom on Netflix and my lead character Smurf is dealing with stage 4 skin cancer So let's just start there Medics is here on the planet to help diagnose skin cancer early. Is that correct? That's absolutely correct And for those of you out there who are not following medics you should be so just give us a quick overview on what medics is So medics is a company that has a visual technology that allows image capture Not only on the top of the skin, but below the skin So it allows us to take a look at a suspicious molar lesion and be able to get that diagnosed by a dermatologist Within 72 hours, and that's the most important part is triage unit so we can get at the people who have a melanoma and deal with it Right away. I got into an argument over you recently Mike with an investor He's like I can just take my phone and scan You know a mole and I can find it if I have cancer and I'm like no no you've got to look at medics That's not correct Correct me and help our audience understand why that is not the way to go Right So what we have is a bunch of technologies that are out in the marketplace that are what we call a class one device They'll take a picture of the top of the skin, and that's it Dermatologists and here's the interesting statistic when you send those across the internet 40% of those are rejected by the dermatologist because there's not enough information Medics's device is a class 2 device which looks under the skin and gives a view called pathophysiology views It'll complicate it on the word side, but what it does is it tells you the structure under the skin It's the only device in the world that does it Technology of that nature allows a dermatologist to make an accurate assessment every time So a class 2 device that also has distribution you just made an agreement for Canada the USA and Israel Can you tell us a little bit more about this deal right? So we've been really fortunate to meet this group called Vita for life So Vita is a relationship. We've already had we've given Vita the exclusive rights to Brazil It's a huge market for us two hundred and twelve million people and the interesting part about Brazil We never see pictures in Brazil without people half clad and lots of sun on them and what they do is they catch They catch melanomas down in Brazil in stage three and stage four when it's really late and very expensive to treat We've had great experience with them and it turns out they have deep relationships both in Israel Canada and the US so we opened up our channel to give them a non-exclusive right to take our technology into that And we've been really really pleased with the original like the With the starting work that they've done there They've opened up some pretty big channels for us already And of course there's many shareholders out there interested in the life sciences and the diagnostic technology Can you tell me when someone like myself can get access to this type of technology here in Toronto? It's a great question We're under some NDAs right now, but I will say this coming very shortly We'll start to go into a national chain And we have a couple of national chains that we're dealing with right now in Canada And we will be able to have this technology I'm guessing early by the fall where you'll be able to just walk into a local pharmacy or Supply clinic of that nature and be able to be tested right away Well as a shareholder and I am a shareholder of medx Can you tell me a little bit more about this news release? I saw as well about your deal in Spain Okay, so now that one there's a pretty exciting one. This is a company called Sanitas Sanitas is owned by a company called Bupa, which is a large insurance company globally large insurance company So Spain has had a 50% increase over the last decade in the incidence of skin cancer So they wanted to do a trial with us They bought 3,000 scans from us that they paid for us and set it up in 12 of their best clients These are national global companies. They have over 1200 facilities Sanitas manages private clinics and hospitals And so what they did was they ran of the 3000 we run about 1200 of them so far And we've got over a hundred melanomas in that test Sanitas's idea behind this is that we can catch enough Melanomas that this would be worldwide for their global policy holders as a very good way of getting at the marketplace and getting prevention out There which is what they're all about. So since I started following medx in the new year You've had almost a dozen news releases. So you're putting out news releases regularly What should interested parties know about your revenue presently and in this upcoming year, right? So so guidance on the revenue kind of looks like this. We have 1500 installs We go from last year's revenue, which was about 1.2 million to about eight and a half million in revenue Now we're talking about well over 15,000 potential installs in the market right now We're pretty comfortable with a number of a 1500 within the next couple quarters And in doing that that gives the revenue numbers of eight and a half $8.5 million of that let me say three million of that will be hardware sales 5.4 of it will be recurring revenue in our SaaS model. So we're pretty comfortable where we are I think the marketplace is waiting for those revenue numbers to start to show in the next couple quarters Well, I'll tell you Mike is always we appreciate the update. Thanks for stopping by pleasure. Nice to see you again, Tracy